Radiopharmaceutical Market: Global Growth and Strategic Analysis of Diagnostic and Therapeutic Applications in Nuclear Medicine
The radiopharmaceutical market, a cornerstone of nuclear medicine, is experiencing substantial growth driven by its dual utility in both diagnostic imaging and targeted therapy for various diseases, notably oncology, cardiology, and neurology. These specialized agents, which incorporate a radioactive isotope (radioisotope) with a pharmaceutical compound, enable non-invasive visualization of physiological functions using modalities like Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). The market is heavily propelled by the rising global incidence of chronic diseases, particularly cancer and cardiovascular ailments, for which radiopharmaceuticals offer increasingly precise diagnostic capabilities and personalized treatment options. The dominance of diagnostic radioisotopes like Technetium-99m and Fluorine-18 (FDG-PET) underscores their widespread adoption in early disease detection and staging. However, the fastest growth is often observed in the therapeutic segment, where agents like Lutetium-177 and Yttrium-90 are revolutionizing cancer treatment…